Raymond James cuts target from USD 475 to USD 450. UnitedHealth Group stock falls 3.15 percent

Published on 10/16/2026 at 15:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At EUR 357.00 on October 16, 2026, UnitedHealth Group stock is 3.15 percent below Xetra close. Third-quarter revenue reached USD 112.69 billion.

Target change and valuation

On October 15, 2026, Raymond James lowered its UnitedHealth Group target from USD 475.00 to USD 450.00.
UnitedHealth reported third-quarter revenue of USD 112.69 billion on October 13, 2026.
UnitedHealth Group stock costs EUR 357.00 at Lang & Schwarz on October 16, 2026 at 3:37 p.m. CEST, 3.15 percent below the Xetra close of October 15, 2026.
UnitedHealth Group had a USD 361.1 billion market capitalization and a P/E ratio of 22.85 on October 16, 2026.

Redaktionelles Börsenparkettfoto mit grünen Kursbildschirmen, Händlern und dynamischer Handelsatmosphäre — UnitedHealth Group US91324P1021 am NYSE-Börsenparkett mit grünen Healthcare-Kurscharts und sehr aktiven Börsenhändlern, Illustration mit AI erstellt.

Raymond James lowered its UnitedHealth Group price target from USD 475.00 to USD 450.00 on October 15, 2026, while maintaining an Outperform rating, according to Investing.com. The new target is 11.85 percent above the USD 402.32 price on the New York Stock Exchange at 9:49 a.m. EDT on October 16, 2026. At Lang & Schwarz, the stock was trading at EUR 357.00 on October 16, 2026 at 3:37 p.m. CEST, down 3.15 percent versus the Xetra close of October 15, 2026 at EUR 368.60.

Third-quarter revenue was USD 112.69 billion

UnitedHealth Group reported USD 112.69 billion in revenue for the third quarter of 2026 on October 13, 2026. Earnings from operations were USD 6.60 billion, net margin was 3.60 percent and operating cash flow was USD 5.10 billion. Revenue was USD 113.16 billion in the third quarter of 2025, a decline of 0.41 percent year over year.

UnitedHealth trades below its yearly high

The EUR 357.00 Lang & Schwarz price stood 10.89 percent below the EUR 400.60 52-week high and 60.31 percent above the EUR 222.70 52-week low on October 16, 2026. The same-day euro range from the Xetra listing was EUR 360.80 to EUR 366.60, putting the Lang & Schwarz quote below that intraday range. UnitedHealth Group's third-quarter report also identified medical costs, regulatory changes and litigation as risks to future results.

Valuation uses USD 361.1 billion

UnitedHealth Group had a market capitalization of USD 361.1 billion, a P/E ratio of 22.85 and a trailing dividend yield of 2.00 percent on October 16, 2026. Raymond James said its lower target reflected a valuation multiple of 16 times estimated 2028 earnings per share and concerns about midterm elections and potential changes to risk adjustment and quality-rating programs.

Comparison with peers

UnitedHealth Group: minus 3.15 percent, P/E 22.85, market capitalization USD 361.1 billion

Humana (NYSE, USD): minus 1.85 percent, P/E 40.14, market capitalization USD 50.9 billion

CVS Health (NYSE, USD): plus 0.08 percent, P/E 24.51, market capitalization USD 118.5 billion

Price and the Xetra close

The current quotation places UnitedHealth Group below its Xetra close of October 15, 2026, while the US listing was also lower at the recorded morning price on October 16, 2026. The company operates through UnitedHealthcare, Optum Health, Optum Insight and Optum Rx.

UnitedHealth Group was trading at EUR 357.00 at Lang & Schwarz on October 16, 2026 at 3:37 p.m. CEST, 3.15 percent below the Xetra close of October 15, 2026 at EUR 368.60. The further course of trading is shown by the continuously updated real-time quote of UnitedHealth Group stock.